Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00319969 · ClinicalTrials.gov registry record · Phase 2

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

A Phase 2 study of Small-cell Lung Cancer, sponsored by Celgene Corporation.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target
20
Study locations

NCT00319969 is a Phase 2 study of Small-cell Lung Cancer that has completed, run by Celgene Corporation. The registered enrollment target is 76 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00319969, a Phase 2 study of Small-cell Lung Cancer, has completed, sponsored by Celgene Corporation.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG Topotecan
  • DRUG Amrubicin

Study Locations (20)

Maryland

  • Sinai Hospital of Baltimore - Baltimore
  • Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building - Baltimore
  • Maryland Oncology Hematology, PA - Columbia
  • Alliance Hematology Oncology, PA - Carroll County Cancer Center - Westminster

Illinois

  • Cancer Care & Hematology Specialists of Chicago - Niles
  • Oncology & Hematology of Central Illinois - Peoria
  • Blessing Cancer Center - Quincy

California

  • Alta Bates Medical Center - Comprehensive Cancer Center - Berkeley
  • Moores UCSD Cancer Center - La Jolla

Colorado

  • Rocky Mountain Cancer Center - Denver - Denver
  • Rocky Mountain Cancer Center - Sky Ridge - Lone Tree

Florida

  • Ocala Oncology Center - Ocala
  • Cancer Centers of Florida, PA - Ocoee

Indiana

  • Central Indiana Cancer Centers - Indianapolis
  • Hope Center - Terre Haute

Alabama

  • Birmingham Hematology & Oncology - Birmingham

Arizona

  • Hematology Oncology Associates - Phoenix

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2006-04
Est. Completion 2009-01
Phase Phase 2

Sponsor

Celgene Corporation

40 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00319969

The ClinicalTrials.gov registry entry for NCT00319969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Topotecan is the first listed.

NCT00319969 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Maryland, Illinois, California.

Frequently Asked Questions

What is clinical trial NCT00319969 about?

NCT00319969 is a clinical study titled "Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.". The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.

What is the current status of trial NCT00319969?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2006-04. Estimated completion is 2009-01.

What conditions does trial NCT00319969 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT00319969?

The interventions under investigation include: Topotecan (DRUG), Amrubicin (DRUG).

Who is sponsoring clinical trial NCT00319969?

This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00319969 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.